AHA and ACC Update Cardiovascular Management Guideline for Noncardiac Surgery
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 1, 2024 -- In a clinical practice guideline issued by the American College of Cardiology and American Heart Association, published online Sept. 24 in both Circulation and the Journal of the American College of Cardiology, updated recommendations are presented for the perioperative cardiovascular management of noncardiac surgery.
Annemarie Thompson, M.D., from Duke University Hospital in Durham, North Carolina, and colleagues note that a stepwise approach to perioperative cardiac assessment can help clinicians determine whether surgery should proceed or whether a pause for additional evaluation is necessary. For patients undergoing noncardiac surgery, cardiovascular screening and treatment should adhere to the same indications as for nonsurgical patients, with careful timing to avoid delays in surgery. Stress testing should be performed judiciously, especially for those at lower risk and only in those in whom testing would be appropriate, regardless of planned surgery.
When managing patients with complex anatomy or unstable cardiovascular disease, team-based care should be emphasized, the authors note. There are significant perioperative implications for new therapies for management of diabetes, heart failure, and obesity. To minimize the risk for perioperative ketoacidosis associated with their use, sodium glucose-cotransporter 2 inhibitors should be discontinued three to four days before surgery. Myocardial injury after noncardiac surgery is a newly identified disease process, which should not be ignored. The risk for stroke is increased for patients with newly diagnosed atrial fibrillation identified during or after noncardiac surgery. Only patients at highest risk for thrombotic complications should use perioperative bridging of oral anticoagulant therapy.
"This new guideline is a comprehensive review of the latest research to help inform clinicians who manage perioperative patients, with the ultimate goal of restoring health and minimizing cardiovascular complications," Thompson said in a statement.
Several authors disclosed ties to the biopharmaceutical and medical device industries.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-02 06:00
Read more
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
- Ultra-processed Foods May Raise Colon Cancer Risk
- Itacitinib Helps Prevent Graft Versus Host Disease in Stem Cell Transplant Recipients
- Some Breast Cancer Patients May Not Need Post-Op Chest Wall Radiation
- FDA Asks Biden Administration to Limit Nicotine in Tobacco Products
- Panel of Biomarkers Can Distinguish Stable, Exacerbation States in COPD
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions